Hydromorphone 10mg/ml Inj, 50ml

Manufacturer TEVA Active Ingredient Hydromorphone Injection(hye droe MOR fone) Pronunciation hye droe MOR fone
WARNING: This is an opioid drug. Opioid drugs can put you at risk for drug use disorder. These can lead to overdose and death. You will be watched closely while taking this drug.Severe breathing problems may happen with this drug. The risk is highest when you first start taking this drug or any time your dose is raised. These breathing problems can be deadly. Call your doctor right away if you have slow, shallow, or trouble breathing. Even one dose of this drug may be deadly if it is taken by someone else or by accident, especially in children. If this drug is taken by someone else or by accident, get medical help right away.Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.Severe side effects have happened when opioid drugs were used with benzodiazepines, alcohol, marijuana, other forms of cannabis, or street drugs. This includes severe drowsiness, breathing problems, and death. Benzodiazepines include drugs like alprazolam, diazepam, and lorazepam. If you have questions, talk with the doctor.Many drugs interact with this drug and can raise the chance of side effects like deadly breathing problems. Talk with your doctor and pharmacist to make sure it is safe to use this drug with all of your drugs.Get medical help right away if you feel very sleepy, very dizzy, or if you pass out. Caregivers or others need to get medical help right away if the patient does not respond, does not answer or react like normal, or will not wake up.If you are pregnant or plan to get pregnant, talk with your doctor right away about the benefits and risks of using this drug during pregnancy. Using this drug for a long time during pregnancy may lead to withdrawal in the newborn baby. Withdrawal in the newborn can be life-threatening if not treated.Make sure you have the right drug; there is more than one strength. A lower strength may not ease pain well enough. A higher strength could lead to accidental overdose and death.Certain strengths of this drug may only be used by people who have been taking drugs like this drug and are used to their effects. The use of these strengths by people who have not been taking drugs like this drug may cause very bad and sometimes deadly breathing problems. Talk with the doctor. @ COMMON USES: It is used to manage pain when non- opioid pain drugs do not treat your pain well enough or you cannot take them.
🏷️
Drug Class
Opioid analgesic
🧬
Pharmacologic Class
Opioid agonist
🀰
Pregnancy Category
Not available
βœ…
FDA Approved
Jan 1942
βš–οΈ
DEA Schedule
Schedule II

Overview

ℹ️

What is this medicine?

Hydromorphone is a strong pain medicine, similar to morphine, used to treat moderate to severe pain. It works by changing how your brain and nervous system respond to pain. This injection is a concentrated form, often used in hospitals for patients who need strong pain relief.
πŸ“‹

How to Use This Medicine

Taking Your Medication

To use this medication correctly, follow your doctor's instructions and read all the information provided. It's essential to follow the instructions carefully. This medication is administered via injection into a muscle, vein, or the fatty layer under the skin.

Storing and Disposing of Your Medication

If you need to store this medication at home, consult with your doctor, nurse, or pharmacist to determine the proper storage method.

Missing a Dose

If you miss a dose, contact your doctor to receive guidance on what to do next.
πŸ’‘

Lifestyle & Tips

  • Avoid alcohol and other sedating medications (e.g., tranquilizers, sleeping pills) unless specifically approved by your doctor, as this can increase the risk of serious side effects like severe drowsiness and breathing problems.
  • Do not drive or operate heavy machinery until you know how this medication affects you, as it can cause dizziness and drowsiness.
  • To prevent constipation, drink plenty of fluids, eat fiber-rich foods, and discuss a bowel regimen (e.g., laxatives) with your healthcare provider.
  • If you are receiving this medication at home, ensure it is stored securely, out of reach of children and pets, to prevent accidental ingestion.

Dosing & Administration

πŸ‘¨β€βš•οΈ

Adult Dosing

Standard Dose: Highly individualized. For opioid-tolerant patients, initial dose should be based on prior opioid exposure. For IV, typically 0.2-1 mg every 2-3 hours as needed. For SC/IM, typically 1-2 mg every 2-3 hours as needed. The 10mg/ml concentration is for opioid-tolerant patients requiring higher doses.
Dose Range: 0.2 - 10 mg

Condition-Specific Dosing:

acute_pain_iv_initial: 0.2-1 mg every 2-3 hours as needed, titrate to effect
chronic_pain_iv_continuous_infusion: Initiate at 0.5-1 mg/hr, titrate based on patient response and previous opioid use. Max dose highly variable.
opioid_tolerant_patients: Higher initial doses may be appropriate, based on calculation from prior opioid daily dose.
πŸ‘Ά

Pediatric Dosing

Neonatal: Not established (use with extreme caution, if at all, due to risk of respiratory depression)
Infant: Not established (use with extreme caution, if at all, due to risk of respiratory depression)
Child: Not established (use with extreme caution, if at all, due to risk of respiratory depression). Limited data, typically 0.015 mg/kg/dose IV/SC/IM every 4-6 hours, not to exceed 0.08 mg/kg/dose. Max single dose 2 mg.
Adolescent: Dosing similar to adult, but start with lower end of adult range and titrate carefully.
βš•οΈ

Dose Adjustments

Renal Impairment:

Mild: No specific dose adjustment, but monitor closely.
Moderate: Reduce initial dose by 25-50% and extend dosing interval. Monitor closely for respiratory depression and sedation.
Severe: Reduce initial dose by 50-75% and extend dosing interval. Avoid if possible. Monitor closely.
Dialysis: Use with extreme caution. Hydromorphone is not significantly removed by hemodialysis. Reduce dose significantly and monitor closely.

Hepatic Impairment:

Mild: No specific dose adjustment, but monitor closely.
Moderate: Reduce initial dose by 25-50% and extend dosing interval. Monitor closely for respiratory depression and sedation.
Severe: Reduce initial dose by 50-75% and extend dosing interval. Avoid if possible. Monitor closely.

Pharmacology

πŸ”¬

Mechanism of Action

Hydromorphone is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), peripheral tissues, and gastrointestinal tract. Its primary therapeutic effects (analgesia, sedation) are mediated through activation of mu-opioid receptors. It also produces respiratory depression, miosis, euphoria, and physical dependence.
πŸ“Š

Pharmacokinetics

Absorption:

Bioavailability: Not applicable for IV/IM/SC. Oral bioavailability is low (approx. 30-35%).
Tmax: IV: 5-10 minutes; IM: 30-60 minutes; SC: 30-90 minutes
FoodEffect: Not applicable for injectable forms.

Distribution:

Vd: Approximately 4 L/kg
ProteinBinding: Approximately 8-19%
CnssPenetration: Yes

Elimination:

HalfLife: Approximately 2-3 hours (IV/IM/SC)
Clearance: Approximately 1.9 L/min
ExcretionRoute: Renal (primarily as H3G)
Unchanged: <10% (renal)
⏱️

Pharmacodynamics

OnsetOfAction: IV: within 5 minutes; IM/SC: 15-30 minutes
PeakEffect: IV: 10-20 minutes; IM/SC: 30-90 minutes
DurationOfAction: IV/IM/SC: 3-5 hours

Safety & Warnings

⚠️

BLACK BOX WARNING

RISK OF ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Hydromorphone Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing and monitor all patients regularly for the development of these behaviors and conditions. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion of hydromorphone injection, especially by children, can result in a fatal overdose. Prolonged use of hydromorphone injection during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
⚠️

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek immediate medical attention:

Signs of an allergic reaction, such as:
+ Rash
+ Hives
+ Itching
+ Red, swollen, blistered, or peeling skin (with or without fever)
+ Wheezing
+ Tightness in the chest or throat
+ Difficulty breathing, swallowing, or talking
+ Unusual hoarseness
+ Swelling of the mouth, face, lips, tongue, or throat
Signs of low blood sugar, including:
+ Dizziness
+ Headache
+ Feeling sleepy or weak
+ Shaking
+ Rapid heartbeat
+ Confusion
+ Hunger
+ Sweating
Severe dizziness or fainting
Confusion
Severe constipation or stomach pain, which may indicate a serious bowel problem
Abnormal heartbeat (fast, slow, or irregular)
Breathing difficulties, including:
+ Slow or shallow breathing
+ Noisy breathing
+ Sleep apnea (breathing problems during sleep)
Hallucinations (seeing or hearing things that are not there)
Mood changes
Seizures
Shakiness
Difficulty urinating
Uncontrolled eye movements
Trouble controlling body movements
Changes in vision
Chest pain or pressure
Balance problems
Memory problems or loss
Thoughts of self-harm or suicide
Swelling in the arms or legs

Serotonin Syndrome: A Potentially Life-Threatening Condition

If you take this medication with certain other drugs, you may be at risk for serotonin syndrome, a severe and potentially deadly condition. Seek medical help immediately if you experience:

Agitation
Balance problems
Confusion
Hallucinations
Fever
Abnormal heartbeat (fast or irregular)
Flushing
Muscle twitching or stiffness
Seizures
Shivering or shaking
Excessive sweating
Severe diarrhea, nausea, or vomiting
Severe headache

Long-Term Use and Hormonal Changes

Prolonged use of opioid medications like this one may lead to decreased sex hormone levels. If you experience any of the following, contact your doctor:

Decreased interest in sex
Fertility problems
Irregular or absent menstrual periods
Ejaculation problems

Other Possible Side Effects

While many people may not experience side effects or only have mild ones, it's essential to be aware of the following:

Constipation
Diarrhea
Stomach pain
Nausea or vomiting
Decreased appetite
Dizziness
Drowsiness
Fatigue
Weakness
Dry mouth
Flushing
Excessive sweating
Headache
Itching
Sleep disturbances

If any of these side effects bother you or persist, contact your doctor for guidance. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Slow or shallow breathing (less than 10 breaths per minute)
  • Extreme drowsiness or difficulty waking up
  • Dizziness or lightheadedness when standing up
  • Confusion or disorientation
  • Severe constipation or inability to have a bowel movement
  • Signs of an allergic reaction (rash, itching, swelling of face/lips/tongue)
  • Pinpoint pupils
πŸ“‹

Before Using This Medicine

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following:

Any allergies you have, including allergies to this medication, its components, or other substances. Be sure to describe the allergic reaction you experienced, including any symptoms that occurred.
Certain health conditions, such as:
+ Respiratory problems, including asthma, breathing difficulties, or sleep apnea
+ Elevated carbon dioxide levels in the blood
+ Stomach or bowel blockage or narrowing
Recent use of specific medications for depression or Parkinson's disease within the last 14 days, including:
+ Isocarboxazid
+ Phenelzine
+ Tranylcypromine
+ Selegiline
+ Rasagiline
Note: Combining these medications can lead to severely high blood pressure.
Current use of certain medications, such as:
+ Buprenorphine
+ Butorphanol
+ Linezolid
+ Methylene blue
+ Nalbuphine
+ Pentazocine

This list is not exhaustive, and it is crucial to disclose all your medications, including prescription and over-the-counter drugs, natural products, and vitamins, as well as any existing health problems. Your doctor and pharmacist need this information to ensure safe use of this medication. Never start, stop, or adjust the dosage of any medication without consulting your doctor.
⚠️

Precautions & Cautions

Important Warnings and Cautions

It is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are taking this medication.

Caution with Daily Activities
Until you know how this medication affects you, avoid driving and other activities that require you to be alert. To minimize the risk of dizziness or fainting, get up slowly from a sitting or lying down position, and be cautious when climbing stairs.

Dosage and Administration
Do not exceed the dose prescribed by your doctor. Taking more than the recommended dose, or taking it more frequently or for a longer period than directed, may increase the risk of severe side effects.

Interactions with Other Medications
Before taking this medication with other strong pain medications or using a pain patch, consult your doctor. If you experience increased pain, sensitivity to pain, or new pain after taking this medication, contact your doctor immediately. Do not take more than the prescribed dose.

Monitoring and Maintenance
If you are taking this medication long-term, your doctor may recommend regular blood tests to monitor your condition.

Allergies and Sensitivities
If you are allergic to sulfites, inform your doctor, as some products may contain sulfites.

Alcohol Interactions
Do not consume alcohol or products containing alcohol while taking this medication, as it may lead to unsafe and potentially life-threatening effects.

Tolerance and Dependence
Long-term or high-dose use of this medication may lead to tolerance, requiring higher doses to achieve the same effect. If you experience a decrease in the medication's effectiveness, consult your doctor. Do not take more than the prescribed dose. Additionally, regular use of opioid medications like this one may cause dependence. If you need to reduce the dose or stop taking the medication, consult your doctor to avoid withdrawal or other severe problems.

Seizure Risk
This medication may increase the risk of seizures, particularly in individuals with a history of seizures. Discuss your risk with your doctor.

Adrenal Gland Problems
Taking an opioid medication like this one may lead to a rare but severe adrenal gland problem. If you experience extreme fatigue, weakness, fainting, severe dizziness, nausea, vomiting, or decreased appetite, contact your doctor immediately.

Special Considerations
If you are 65 or older, use this medication with caution, as you may be more susceptible to side effects.

Breastfeeding
If you are breastfeeding, inform your doctor, as this medication passes into breast milk and may harm your baby. Seek medical attention immediately if your baby appears overly sleepy, limp, or has breathing difficulties.
πŸ†˜

Overdose Information

Overdose Symptoms:

  • Slowed or stopped breathing (respiratory depression)
  • Extreme drowsiness, unresponsiveness, or coma
  • Pinpoint pupils
  • Cold, clammy skin
  • Limp muscles
  • Slowed heart rate
  • Low blood pressure

What to Do:

Seek immediate emergency medical attention. Call 911 or your local emergency number. Administer naloxone if available and trained to do so. Stay with the person until emergency help arrives. Call 1-800-222-1222 (Poison Control) for additional guidance.

Drug Interactions

🚫

Contraindicated Interactions

  • Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of MAOI therapy (risk of serotonin syndrome or severe respiratory depression)
  • Patients with significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected paralytic ileus
πŸ”΄

Major Interactions

  • Benzodiazepines and other CNS depressants (e.g., other opioids, sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, phenothiazines, alcohol): Increased risk of respiratory depression, profound sedation, coma, and death.
  • Serotonergic drugs (e.g., SSRIs, SNRIs, TCAs, triptans, mirtazapine, tramadol, fentanyl): Risk of serotonin syndrome.
  • Mixed agonist/antagonist opioids (e.g., butorphanol, nalbuphine, pentazocine): May reduce analgesic effect or precipitate withdrawal symptoms.
  • Anticholinergic drugs (e.g., atropine, scopolamine, tricyclic antidepressants): Increased risk of urinary retention and severe constipation/paralytic ileus.
🟑

Moderate Interactions

  • Diuretics: Opioids can reduce the efficacy of diuretics by causing release of antidiuretic hormone.
  • Antihypertensives: May cause additive hypotensive effects.
  • P-glycoprotein (P-gp) inhibitors/inducers: May alter hydromorphone concentrations, though hydromorphone is not a major P-gp substrate.
🟒

Minor Interactions

  • Not specifically identified for minor interactions with significant clinical impact.

Monitoring

πŸ”¬

Baseline Monitoring

Pain assessment (intensity, character, location)

Rationale: To establish baseline pain level and guide initial dosing.

Timing: Prior to initiation of therapy

Respiratory rate and depth

Rationale: To assess baseline respiratory function and identify risk for respiratory depression.

Timing: Prior to initiation of therapy

Level of consciousness/sedation score

Rationale: To assess baseline mental status and identify risk for excessive sedation.

Timing: Prior to initiation of therapy

Blood pressure and heart rate

Rationale: To assess baseline cardiovascular status.

Timing: Prior to initiation of therapy

Bowel function

Rationale: To assess baseline bowel habits and anticipate opioid-induced constipation.

Timing: Prior to initiation of therapy

πŸ“Š

Routine Monitoring

Pain assessment

Frequency: Every 15-30 minutes after IV dose until stable, then every 2-4 hours or as needed; for continuous infusion, every 1-2 hours initially, then every 4 hours.

Target: Patient-specific pain goal (e.g., pain score <4/10)

Action Threshold: Pain score above target, requiring dose adjustment or rescue medication.

Respiratory rate and depth

Frequency: Every 15-30 minutes after IV dose until stable, then every 2-4 hours or as needed; for continuous infusion, every 1-2 hours initially, then every 4 hours.

Target: Typically >10-12 breaths/min (adults), regular rhythm, adequate depth.

Action Threshold: Respiratory rate <10 breaths/min, shallow breathing, or signs of distress; administer naloxone if indicated.

Level of consciousness/sedation score (e.g., Pasero Opioid-Induced Sedation Scale)

Frequency: Every 15-30 minutes after IV dose until stable, then every 2-4 hours or as needed; for continuous infusion, every 1-2 hours initially, then every 4 hours.

Target: Alert or mildly drowsy, easily aroused.

Action Threshold: Excessive sedation (e.g., difficult to arouse, somnolent); hold dose, consider naloxone.

Blood pressure and heart rate

Frequency: Every 1-4 hours or as needed.

Target: Within patient's normal range.

Action Threshold: Significant hypotension or bradycardia.

Bowel function

Frequency: Daily

Target: Regular bowel movements (e.g., every 1-2 days)

Action Threshold: No bowel movement for 3 days; initiate laxative regimen.

πŸ‘οΈ

Symptom Monitoring

  • Respiratory depression (slow, shallow breathing, cyanosis)
  • Excessive sedation/somnolence
  • Dizziness/lightheadedness
  • Nausea/vomiting
  • Constipation
  • Pruritus
  • Urinary retention
  • Signs of allergic reaction (rash, hives, swelling)
  • Signs of opioid withdrawal (in physically dependent patients if dose reduced or discontinued abruptly)

Special Patient Groups

🀰

Pregnancy

Prolonged use of hydromorphone during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated. Use only if the potential benefit justifies the potential risk to the fetus. Monitor neonates for signs of NOWS.

Trimester-Specific Risks:

First Trimester: Limited human data. Potential for increased risk of major congenital malformations with first trimester opioid exposure, though data are conflicting.
Second Trimester: Risk of NOWS increases with prolonged use.
Third Trimester: High risk of NOWS with prolonged use. Risk of respiratory depression in the neonate if administered close to delivery.
🀱

Lactation

Hydromorphone is excreted into breast milk. Monitor breastfed infants for signs of sedation, respiratory depression, poor feeding, and withdrawal symptoms. A single dose is generally considered low risk, but repeated doses or high doses are not recommended. Consider alternative analgesics or temporary cessation of breastfeeding.

Infant Risk: Moderate risk (L3). Potential for infant sedation, respiratory depression, and withdrawal.
πŸ‘Ά

Pediatric Use

Use with extreme caution due to increased sensitivity to respiratory depression. Dosing must be individualized and carefully titrated. Not recommended for neonates or infants due to lack of established safety and efficacy.

πŸ‘΄

Geriatric Use

Start with lower doses and titrate slowly due to increased sensitivity to opioids, decreased renal/hepatic function, and increased risk of respiratory depression, sedation, and falls. Monitor closely.

Clinical Information

πŸ’Ž

Clinical Pearls

  • Hydromorphone 10mg/ml is a highly concentrated formulation, primarily intended for opioid-tolerant patients or those requiring rapid titration in acute severe pain (e.g., palliative care, critical care). Extreme caution is needed to prevent dosing errors.
  • Always dilute the 10mg/ml concentration if administering via IV push, unless specifically ordered undiluted for rapid administration in specific clinical scenarios (e.g., rapid sequence intubation, severe acute pain in opioid-tolerant patients). Standard IV push concentration is often 0.2 mg/ml or 1 mg/ml.
  • Hydromorphone has a rapid onset and relatively short duration of action, making it suitable for acute pain management and titration, but requiring frequent dosing for sustained analgesia.
  • Patients with renal impairment are at higher risk for accumulation of the active metabolite H3G, which can cause neuroexcitatory symptoms (myoclonus, delirium, seizures). Dose reduction is crucial.
  • Tolerance and physical dependence can develop with prolonged use. Do not abruptly discontinue in physically dependent patients to avoid withdrawal symptoms.
  • Naloxone should be readily available when administering hydromorphone, especially in opioid-naive patients or those at high risk for respiratory depression.
πŸ”„

Alternative Therapies

  • Morphine (IV, SC, IM)
  • Fentanyl (IV, IM)
  • Oxycodone (oral, not injectable for acute pain)
  • Meperidine (limited use due to neurotoxic metabolite)
  • Non-opioid analgesics (e.g., NSAIDs, acetaminophen) for less severe pain or as adjuncts to reduce opioid dose.
πŸ’°

Cost & Coverage

Average Cost: Varies widely, typically $50-$200+ per 50ml vial (10mg/ml)
Generic Available: Yes
Insurance Coverage: Tier 2-3 (often requires prior authorization for high doses or chronic use)
πŸ“š

General Drug Facts

It is essential to monitor your symptoms and health problems while taking this medication. If you notice no improvement or a worsening of your condition, contact your doctor promptly.

To ensure safe use, keep the following guidelines in mind:
- Do not share your medication with others, and never take someone else's medication.
- Store all medications in a secure location, out of reach of children and pets.
- Properly dispose of unused or expired medications. Unless instructed to do so, avoid flushing them down the toilet or pouring them down the drain. If you are unsure about the best disposal method, consult your pharmacist. You may also want to explore drug take-back programs available in your area.

This medication is accompanied by a Medication Guide, which provides crucial information. Read this guide carefully and review it each time you receive a refill. If you have any questions or concerns about this medication, discuss them with your doctor, pharmacist, or other healthcare provider.

In the event of an overdose, a medication called naloxone can be administered to help treat the condition. Consult your doctor or pharmacist about obtaining or using naloxone. If you suspect an overdose has occurred, seek immediate medical attention, even if naloxone has been used. Be prepared to provide information about the medication taken, the amount, and the time it was taken.

If you believe an overdose has occurred, contact your local poison control center or seek medical care right away. When seeking help, be prepared to provide details about the medication, including the amount taken and the time of the incident.